scispace - formally typeset
Search or ask a question
Institution

Hebron University

EducationHebron, Palestinian Territory
About: Hebron University is a education organization based out in Hebron, Palestinian Territory. It is known for research contribution in the topics: Population & Cancer. The organization has 2714 authors who have published 4180 publications receiving 163736 citations.


Papers
More filters
Journal ArticleDOI
TL;DR: Recent developments in the field of RIC were discussed with a focus on new insights into the underlying mechanisms, the diversity of non-cardiac protection, new clinical applications, and large outcome studies.
Abstract: In 1993, Przyklenk and colleagues made the intriguing experimental observation that ‘brief ischemia in one vascular bed also protects remote, virgin myocardium from subsequent sustained coronary artery occlusion’ and that this effect ‘…. may be mediated by factor(s) activated, produced, or transported throughout the heart during brief ischemia/reperfusion’. This seminal study laid the foundation for the discovery of ‘remote ischemic conditioning’ (RIC), a phenomenon in which the heart is protected from the detrimental effects of acute ischemia/reperfusion injury (IRI), by applying cycles of brief ischemia and reperfusion to an organ or tissue remote from the heart. The concept of RIC quickly evolved to extend beyond the heart, encompassing inter-organ protection against acute IRI. The crucial discovery that the protective RIC stimulus could be applied non-invasively, by simply inflating and deflating a blood pressure cuff placed on the upper arm to induce cycles of brief ischemia and reperfusion, has facilitated the translation of RIC into the clinical setting. Despite intensive investigation over the last 20 years, the underlying mechanisms continue to elude researchers. In the 8th Biennial Hatter Cardiovascular Institute Workshop, recent developments in the field of RIC were discussed with a focus on new insights into the underlying mechanisms, the diversity of non-cardiac protection, new clinical applications, and large outcome studies. The scientific advances made in this field of research highlight the journey that RIC has made from being an intriguing experimental observation to a clinical application with patient benefit.

107 citations

Journal ArticleDOI
TL;DR: BP can be inferred from PPG using DBN-RBM modeling techniques, but its intrinsic variability and its wide limits of agreement do not allow clinical application at this time.
Abstract: To develop and validate a continuous non-invasive blood pressure (BP) monitoring system using photoplethysmography (PPG) technology through pulse oximetry (PO). This prospective study was conducted at a critical care department and post-anesthesia care unit of a university teaching hospital. Inclusion criteria were critically ill adult patients undergoing invasive BP measurement with an arterial catheter and PO monitoring. Exclusion criteria were arrhythmia, imminent death condition, and disturbances in the arterial or the PPG curve morphology. Arterial BP and finger PO waves were recorded simultaneously for 30 min. Systolic arterial pressure (SAP), mean arterial pressure (MAP), and diastolic arterial pressure (DAP) were extracted from computer-assisted arterial pulse wave analysis. Inherent traits of both waves were used to construct a regression model with a Deep Belief Network-Restricted Boltzmann Machine (DBN-RBM) from a training cohort of patients and in order to infer BP values from the PO wave. Bland–Altman analysis was performed. A total of 707 patients were enrolled, of whom 135 were excluded. Of the 572 studied, 525 were assigned to the training cohort (TC) and 47 to the validation cohort (VC). After data processing, 53,708 frames were obtained from the TC and 7,715 frames from the VC. The mean prediction biases were −2.98 ± 19.35, −3.38 ± 10.35, and −3.65 ± 8.69 mmHg for SAP, MAP, and DAP respectively. BP can be inferred from PPG using DBN-RBM modeling techniques. The results obtained with this technology are promising, but its intrinsic variability and its wide limits of agreement do not allow clinical application at this time.

107 citations

Journal ArticleDOI
TL;DR: The clinical, pathological, and therapeutic aspects of inflammatory and immune-mediated late-onset adverse reactions related to soft tissue filler injections are thoroughly reviewed herein.
Abstract: An ever-increasing number of persons seek medical solutions to improve the appearance of their aging skin or for aesthetic and cosmetic indications in diverse pathological conditions, such as malformations, trauma, cancer, and orthopedic, urological, or ophthalmological conditions. Currently, physicians have many different types of dermal and subdermal fillers, such as non-permanent, permanent, reversible, or non-reversible materials. Despite the claims of manufacturers and different authors that fillers are non-toxic and non-immunogenic or that complications are very uncommon, unwanted side effects do occur with all compounds used. Implanted, injected, and blood-contact biomaterials trigger a wide variety of adverse reactions, including inflammation, thrombosis, and excessive fibrosis. Usually, these adverse reactions are associated with the accumulation of large numbers of mononuclear cells. The adverse reactions related to fillers comprise a broad range of manifestations, which may appear early or late and range from local to systemic. Clinicians should be aware of them since the patient often denies the antecedent of injection or is unaware of the material employed. Most of these adverse effects seem to have an immunological basis, the fillers acting more as adjuvants than as direct T-cell activators, on a background of genetic predisposition. Their treatment has not been the subject of well-designed studies; management of both acute and systemic reactions is often difficult, and requires anti-inflammatory and occasionally immunosuppressive therapy. The clinical, pathological, and therapeutic aspects of inflammatory and immune-mediated late-onset adverse reactions related to soft tissue filler injections are thoroughly reviewed herein.

107 citations

Journal ArticleDOI
TL;DR: The available studies on spasticity treatment offer some insight to guide clinical practice but are of variable methodological quality and large, well-designed trials are needed to confirm the effectiveness of antispasticity agents and to produce evidence-based treatment algorithms.
Abstract: Background and objectives:Treatment of spasticity poses a major challenge given the complex clinical presentation and variable efficacy and safety profiles of available drugs. We present a systematic review of the pharmacological treatment of spasticity in multiple sclerosis (MS) patients.Methods:Controlled trials and observational studies were identified. Scientific evidence was evaluated according to pre-specified levels of certainty.Results:The evidence supports the use of baclofen, tizanidine and gabapentin as first-line options. Diazepam or dantrolene could be considered if no clinical improvement is seen with the previous drugs. Nabiximols has a positive effect when used as add-on therapy in patients with poor response and/or tolerance to first-line oral treatments. Despite limited evidence, intrathecal baclofen and intrathecal phenol show a positive effect in severe spasticity and suboptimal response to oral drugs.Conclusion:The available studies on spasticity treatment offer some insight to guide ...

106 citations

Journal ArticleDOI
TL;DR: Eribulin mesylate (E7389) is a nontaxane microtubule dynamics inhibitor with a novel mechanism of action that has activity in a variety of in vivo tumor model types, including breast cancer.

106 citations


Authors

Showing all 2723 results

NameH-indexPapersCitations
José Baselga156707122498
M. I. Martínez134125179885
Josep Tabernero11180368982
Jordi Rello10369435994
Xavier Montalban9576252842
James M. Downey9138129506
Enriqueta Felip8362253364
Joaquim Bellmunt8266041472
Joan Montaner8048922413
Marc Miravitlles7665125671
David H. Salat7524136779
Eduard Gratacós7553120178
Alex Rovira7435619586
Ramon Bataller7228319316
Maria Buti7149326596
Network Information
Related Institutions (5)
Memorial Sloan Kettering Cancer Center
65.3K papers, 4.4M citations

89% related

University of Texas MD Anderson Cancer Center
92.5K papers, 4.7M citations

89% related

VU University Medical Center
22.9K papers, 1.1M citations

88% related

Netherlands Cancer Institute
17.2K papers, 1.1M citations

88% related

Mayo Clinic
169.5K papers, 8.1M citations

87% related

Performance
Metrics
No. of papers from the Institution in previous years
YearPapers
20232
202212
2021568
2020545
2019483
2018385